131I labelled F (ab’)2 fragments of monoclonal antibodies against CA 19-9 and CEA (“radioimmunococktail” IMACIS 1) were used in a prospective study (n = 60 patients) and in a retrospective study (n = 32 patients) for the detection of colorectal carcinomas (n = 67) and other gastrointestinal CEA/CA 19-9-producing tumors (n = 32). Sensitivity was 82% and specificity 90%. Immunoscintigraphy proved useful and complementary to CT scan and sonography, especially in the diagnosis of pelvic recurrences and intra-abdominal metastases.
In addition, monoclonal antibody OC 125 (IMACIS 2) was used for the detection of ovarian carcinomas (n = 10) and other CA 125 producing tumors. Immunoscintigraphy was positive in all patients (n = 18) suggesting that this radioimmunological approach could be of use in the staging, therapeutic control and earlier diagnosis of recurrent epithelial ovarian carcinoma.
MachJ.P., CarrelS., MerendaC.. In vivo localization of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice.Nature1974; 248: 704–6.
2.
KöhlerG., MilsteinC.Continuous cultures of fused cells secreting antibodies of predefined specificity.Nature1975; 256: 495–7.
KoprowskiH., GinsburgV.A monoclonal antibody defined antigen associated with gastrointestinal cancer as a ganglioside containing sialylated lacto-N-fucopentaose II.Biol Chem1982; 257: 14365–9.
5.
MagnaniJ.L., BrockhausM., SmithD.F.. A monosialoganglioside is a monoclonal antibody defined antigen of colon carcinoma.Science1981; 212: 55–6.
6.
MagnaniJ.L., SteplewskiZ., KoprowskiH., GinsburgV.Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.Cancer Res1983; 43: 5489–92.
7.
KoproswkiH., HerlynM., StepleswkiZ.Specific antigen in serum of patients with colon carcinoma.Science1981; 212: 53–5.
8.
Del VillanoB.C., BrennanS., BrockP.. Radioimmunometric assay for a monoclonal antibody defined tumor marker Ca 19-9.Clin Chem1983; 29: 549.
9.
ChatalJ.F., SaccaviniJ.C., FumoleauP.. Photo-scanning localization of human tumors, using radio-iodinated monoclonal antibodies to colorectal carcinoma.J Nucl Med1982; 23: 8.
10.
BastR.C., FeeneyM., LazarusH.. Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest1981; 68: 1331–37.
11.
BastR.C., KlugT.C., St. JohnE.. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med1983; 309: 883–7.
12.
KlapdorR., LehmannU., BahloM.. CA 19-9 and CEA in the follow-up of exocrine pancreatic cancer disease.Gastroenterology1984; 86: 1137.
13.
LorenzM., HappJ., HottenrottC.. Klinische Überprüfung eines neuen Tumormarkers (CA 19-9) im Vergleich zum carcino-embryonalen Antigen (CEA) in der chirurgischen prä- und postoperativen Diagnostik.Nucl Med1986; 25: 9–14.
14.
PerkinsA., ArmitageN.C., HarrisonRC;. Planar and SPECT imaging of colon cancer using 111In-CEA antibody (C46).Eur J Nucl Med1985; 11: A18.
15.
KimE.E., De LandF.H., SalyerJ.R., BennettS.J., GoldenbergD.M.Radioimmunodetection of various human carcinomata with radiolabeled antibodies to tumor-associated antigens. In: Medical radionuclide imaging. (Ed. International Atomic Energy Agency), 1981; Vol. 1: 511–18.
16.
MachJ.P., ChatalJ.F., LumbrosoJ.D.. Tumor localization in patients by radiolabeled antibodies against colon carcinoma.Cancer Res1983; 43: 5593–60.
17.
GoldenbergD.M., KimE.E., BennettS.J., NelsonM.O., De LandD.H.Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms.Gastroenterology1983; 84: 524–32.
WahlL.R., ParkerC.W., PhilpottG.W.Improved radioimaging and tumor localization with monoclonal F(ab’)2.J Nucl Med1983; 24: 316–25.
20.
SenekowitschR., BaumR.P., MaulF.D.. Biokinetische Studien zur szintigraphischen Darstellung xenotransplantierter menschlicher Pankreaskarzinome mit 131J-markierten F(ab’)2-Fragmenten verschiedener monoklonaler Antikörper.NucCompact1985; 16: 414–19.
21.
GranowskaM., ShepherdJ., BrittonK.E.. Ovarian cancer: diagnosis using 123I monoclonal antibody in comparison with surgical findings.Nucl Med Comm1984; 5: 485–99.
22.
BaumR.P., MaulF.D., Klapdor. Immunszintigraphie kolorektaler Tumoren mit 131J-markierten monoklonalen Antikörpern (19-9/Anti-CEA): Erste Ergebnisse.NucCompact1985; 16: 121–28.
23.
BaumR.P., MaulF.D., SenekowitschR.. Radioim-munoscintigraphy of CA 19-9/CEA producing tumors using 131I- labeled F(ab’)2 fragments of monoclonal antibodies (19-9/Anti-CEA radioimmunococktail). In: WinklerC., ed. Nuclear medicine in clinical oncology.Berlin-Heidelberg: Springer, 1986; 197–206.
24.
BaumR.P., MaulF.D., SenekowitschR.. Radioim-munoscintigraphy and radioimmunotherapy with monoclonal antibodies (19-9/Anti-CEA and OC 125). In: HöferR., BergmannH., eds. Radioaktive Isotope in Klinik und Forschung.Wien: Egermann, 1986; 17. Band, Teil 1: 443.
25.
BaumR.P., ChatalJ.F., SaccaviniJ.C.. Radioimmunotherapy with 131I- labelled monoclonal antibodies 19-9/anti-CEA and OC 125.J Nucl Med1986; 6: 1019.
26.
BaumR.P., LorenzM., SenekowitschR.. Clinical experience in cancer diagnosis with radiolabeled monoclonal antibodies in 200 patients and initial attempts at radioimmunotherapy. In: SrivastavaS.C., ed. Radiolabeled monoclonal antibodies for imaging and therapy. Potential, problems, and prospects.New York: Pergamon Press, 1988.
27.
BaumR.P., ChatalJ.F., SaccaviniJ.C., FumoleauP. (European Study Group). Immunoscintigraphy of epithelial ovarian carcinoma after injection of 131I-labelled F(ab’)2 fragments from monoclonal antibody OC 125.Results of a European Multicenter Study. (submitted for publication).
28.
BaumR.P., AlbrechtM., ThalerC.J.. Immunoscintigraphy of ovarian cancer with monoclonal antibody OC 125. First results. In: SchmidtH.A.E., EmrichD., eds. Nuklearmedizin. Clinical demands in nuclear medicine.Stuttgart New York: Schattauer, 1987; 417.
29.
BurraggiG.L., CallegaroL., TurrinA.. Radioim-munodetection of colorectal carcinoma with an anti-CEA antibody. In: SchmidtH.A.E., EllP.J., BrittonK.E., eds. Nuklearmedizin in Forschung und Praxis.Stuttgart- New York: Schattauer, 1986; 430.
30.
BuraggiG.L., CallegaroL., MarianiG.. Imaging with 131I-labeled monoclonal antibodies to a high-molecular weight melanoma-associated antigen in patients with melanoma: Efficacy of whole immunoglobulin and its F(ab’)2 fragments.Cancer Res1985; 45: 3378–87.
31.
DelaloyeB., Bischof-DelaloyeA., BucheggerF.. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab’)2 fragments from monoclonal anti-car-cinoembryonic antigen antibodies.J Clin Invest1986; 77: 301–11.
32.
EpenetosA.A., MatherS., GranowskaM.. Targeting of Iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors.Lancet1982; ii: 999–1005.
33.
GranowskaM., BrittonK.E., ShepherdJ.H.. A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer.J Clin Oncol1986; 4: 730–6.
34.
HörG., BaumR.P., MaulF.D.. Immunszinti-graphie bei Rezidiven kolorektaler Karzinome und deren Metastasen. Erste Frankfurter Erfahrungen.Dtsch Ärztebl1986; 83: 2862–68.
35.
LarsonS.M.Radiolabeled monoclonal antitumor antibodies in diagnosis and therapy.J Nucl Med1985; 25: 538–45.
36.
PateiskyN., PhilippK., SkodlerW.D.. Radioim-munodetection in patients with suspected ovarian cancer.J Nucl Med1985; 26: 1369–76.
37.
PerkinsA.C., PimmM.V., BirchM.K.. The preparation and characterisation of 111In-labelled 791 T/36 monoclonal antibody for tumor immunoscintigraphy.Eur J Nucl Med1985; 10: 296–301.
38.
RivaP., PaganelliG., AmadoriD.. Radioimmunodetection of primary and metastatic tumor of G. I. tract by means of 1311 or 111In labelled F(ab’)2 anti-CEA administered by intravenous or intraperitoneal route. In: SchmidtH.A.E., EllP.J., BrittonK.E., eds. Nuklearmedizin in Forschung und Praxis.Stuttgart - New York: Schattauer, 1986; 660.
39.
SenekowitschR., MaulF.D., BaumR.P.. Radioimmunoscintigraphy and immunohistochemical detection of different antigens in human pancreatic carcinoma xenografts with monoclonal antibodies. In: SchmidtH.A.E., EllP.J., BrittonK.E., eds. Nuklearmedizin in Forschung und Praxis.Stuttgart - New York: Schattauer, 1986; 663.
StaabH.J., AndererF.A., HornungA.. Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer.Brit J Cancer1982; 46: 773.
42.
SenekowitschR., KriegelH., BaumR.P., HörG.Biokinetic studies and scintigraphic imaging of human carcinoma xenografts with radiolabeled monoclonal antibodies. In: SrivastavaS.C., ed. Radiolabeled monoclonal antibodies for imaging and therapy.New York: Pergamon Press, 1988.
